ASCO 2016 Update: Immunotherapy and Melanoma

Harold Burstein, Elizabeth Buchbinder

Harold J. Burstein, MD, PhD (right), discusses the latest immunotherapy research with Elizabeth Buchbinder, MD (left).

As one of the hottest topics in cancer research today, immunotherapy took center stage at the 2016 American Society of Clinical Oncology meeting in Chicago. Harold J. Burstein, MD, PhD, a breast oncologist in the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, recently sat down with other oncologists to break down some of the meeting’s more important findings.

Below, he talks with Elizabeth I. Buchbinder, MD, a melanoma specialist, about some of the research related to pembrolizumab (Keytruda), which was used to treat former President Jimmy Carter, and other immunotherapy news.

Watch additional ASCO video updates and learn about other important research presentations.

Comments Sort By Newest

One thought on “ASCO 2016 Update: Immunotherapy and Melanoma

Comments are closed.

Make An Appointment

For adults: 877-960-1562

Quick access: Appointments as soon as the next day for new adult patients

For children: 888-733-4662

All content in these blogs is provided by independent writers and does not represent the opinions or advice of Dana-Farber Cancer Institute or its partners.

Latest Tweets

Dana-Farber @danafarber
Dr. Matthew Davids explores combining ibrutinib with FCR (iFCR) for younger patients with previously-untreated chro… https://t.co/wzVpo47tSa
Dana-Farber @danafarber
“We’re changing the way people are cared for, through #precisionmedicine, precision care, and a total team approach… https://t.co/RnZXsH2rW8
Dana-Farber @danafarber
Cell-weighing method could help doctors choose #cancer drugs: https://t.co/YesjtyxIvR via @MIT https://t.co/0F7wsZSuLJ

Republish our posts on your blog

Interested in sharing one of our stories on your blog? Feel free to republish this content! We just ask that you credit Dana-Farber, link to the original article, and refrain from making edits that change the original context. Questions? Email the editors at insight_blog@dfci.harvard.edu.